I'm LongbridgeAI, I can summarize articles.Advanced Biomed Inc. reported FY2026 results with $127.6K revenue and $6.68M net income, driven by a $14M gain from subsidiary divestitures. The company pivoted from biotech to AI and fintech SaaS via the Acellent acquisition. EPS rose to $5.33 from a $3.18 loss in FY2025.
Advanced Biomed Inc. reported fiscal 2026 results showing initial revenue of $127637 and net income of $6677077 or diluted earnings per share of $5.33, compared with a net loss of $(3,258,969) and EPS of $(3.18) in FY 2025. FY 2026 results include a $14M gain on disposal of subsidiaries related to the company’s strategic pivot and divestitures.
Financial Highlights
- Revenue: $127,637 for FY 2026, compared with $0 for FY 2025 (initial revenue from Acellent agency services).
- Net income: $6,677,077 for FY 2026, compared with net loss $(3,258,969) for FY 2025 (FY2026 includes $14.0M gain on disposal of subsidiaries).
- Diluted EPS: $5.33 for FY 2026, compared with $(3.18) for FY 2025.
Business Highlights
- Strategic pivot from biotechnology to AI and financial algorithmic software completed through divestitures and a refocus of operations.
- Acquired Acellent in April 2026 and began integrating large language model and fintech SaaS capabilities into core offerings.
- Generated initial commercial revenue from Acellent agency services as a proof-of-concept, totaling $127,637 for the year.
- Cost structure shifted away from lab and clinical spend toward cloud infrastructure, data acquisition, and engineering headcount.
- Management is pursuing near-term monetization via SaaS, predictive analytics and agency channels while monitoring receivable collections to fund operations.
Original SEC Filing: Advanced Biomed Inc. [ ADVB ] - 10-K - Oct. 13, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.